Pds biotech receives $1.4 million after selling its net operating loss tax benefits through the new jersey economic development program

Florham park, n.j., april 24, 2023 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease announced the company received $1.4 million from the net sale of tax benefits to an unrelated, profitable new jersey corporation pursuant to the company's participation in the new jersey technology business tax certificate transfer net operating loss (nol) program for state fiscal year 2021.
PDSB Ratings Summary
PDSB Quant Ranking